France to explore expenditure control through reimbursement
This article was originally published in Clinica
France may soon have a new tool to control medical device expenditure within its reimbursement structure when spending levels raise concern. This will be achieved via the new French reimbursement pricing committee for medical devices, CEPS. And while it will need time to settle fully into its active role, the concept of price-volume agreements with manufacturers is unlikely to be far away.
You may also be interested in...
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.